Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
4 minute read

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen, Patented Nicotinamide Riboside, Supplementation Induces A Potent NAD+ Response And Is Associated With Mild Improvement In Parkinson’s Disease

By Benzinga Newsdesk
November 30, 9:36 AM
Building on a growing body of research showcasing NR as a potential therapeutic strategy for PD, this is the first clinical study to showcase the safety, tolerability, and beneficial metabolic effects of high-dose NR at

CDXC

Read More
1 minute read

ChromaDex New Published Phase II Clinical Study Demonstrates That Supplementation With Niagen, Patented Nicotinamide Riboside, Elevates NAD+ Up To Fourfold, Improving Motor Coordination And Eye Movement In Ataxia Telangiectasia Patients

By Benzinga Newsdesk
November 15, 9:35 AM
This is the longest Niagen NR clinical trial to date spanning two years and showcases that long-term Niagen NR is safe and well toleratedStudy highlightsNR supplementation was well tolerated, with no serious adverse

CDXC